Pacira BioSciences (PCRX) Gross Margin (2010 - 2026)

Pacira BioSciences' Gross Margin history runs 17 years deep, the most recent figure standing at 79.47% for Q1 2026.

• On a quarterly basis, Gross Margin fell 22.0% year-over-year to 79.47% in Q1 2026; TTM through Mar 2026 was 79.34%, a 172.0% increase from a year earlier, with the FY2025 full-year figure at 79.39%, up 370.0% from the prior year.
• Gross Margin was little changed at 79.47% in Q1 2026 per PCRX's latest filing, from 79.53% in the prior quarter.
• Across five years, Gross Margin topped out at 112.58% in Q4 2022 and bottomed at 69.43% in Q1 2023.
• The 5-year median for Gross Margin is 76.95% (2024), against an average of 77.62%.
• Across the five-year window, Gross Margin jumped 3708 bps in 2022 and slumped 3889 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 112.58% in 2022, then plunged by 35 bps to 73.69% in 2023, then climbed by 7 bps to 78.7% in 2024, then grew by 1 bps to 79.53% in 2025, then retreated by 0 bps to 79.47% in 2026.
• Per Business Quant, the three latest PCRX Gross Margin figures stand at 79.47% (Q1 2026), 79.53% (Q4 2025), and 80.91% (Q3 2025).